Skip to main content

Human VEGF (Research Grade Bevacizumab Biosimilar) Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB9947

Recombinant Monoclonal Antibody For Research Use Only
R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
MAB9947-100
MAB9947-SP

Key Product Details

Species Reactivity

Human

Applications

Neutralization

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Human IgG1 Clone # Hu101

Product Specifications

Immunogen

Human VEGF-A

Specificity

Detects human VEGF based on Bevacizumab therapeutic antibody. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Bevacizumab. This product is for research use only.

Clonality

Monoclonal

Host

Human

Isotype

IgG1

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Human VEGF (Research Grade Bevacizumab Biosimilar) Antibody

Cell Proliferation Induced by VEGF165and Neutralization by Human VEGF (Bevacizumab Biosimilar) Antibody.

Cell Proliferation Induced by VEGF165and Neutralization by Human VEGF (Bevacizumab Biosimilar) Antibody.

Recombinant Human VEGF165(Catalog # 293-VE) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line) as measured by Resazurin (Catalog # AR002). Proliferation elicited by Recombinant Human VEGF165(10 ng/mL) is neutralized (green line) by increasing concentrations of Human Anti-Human VEGF (Bevacizumab Biosimilar) Monoclonal Antibody (Catalog # MAB9947). The ND50 is typically 10-80 ng/mL.

Applications for Human VEGF (Research Grade Bevacizumab Biosimilar) Antibody

Application
Recommended Usage

Neutralization

Measured by its ability to neutralize VEGF165-induced proliferation in HUVEC human umbilical vein endothelial cells. The Neutralization Dose (ND50) is typically 10-80 ng/mL in the presence of 10 ng/mL Recombinant Human VEGF165.

Formulation, Preparation, and Storage

Purification

Protein A or G purified from cell culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGF

Bevacizumab is a biosimilar directed against VEGF.

Long Name

Vascular Endothelial Growth Factor

Alternate Names

MVCD1, VAS, Vasculotropin, VEGF-A, VEGFA, VPF

Entrez Gene IDs

7422 (Human); 22339 (Mouse); 83785 (Rat); 281572 (Bovine); 403802 (Canine); 493845 (Feline); 30682 (Zebrafish)

Gene Symbol

VEGFA

Additional VEGF Products

Product Documents for Human VEGF (Research Grade Bevacizumab Biosimilar) Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human VEGF (Research Grade Bevacizumab Biosimilar) Antibody

For research use only

Loading...
Loading...
Loading...
Loading...